Salix Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Salix Pharmaceuticals's estimated annual revenue is currently $277.2M per year.
- Salix Pharmaceuticals received $0.8M in venture funding in January 2014.
- Salix Pharmaceuticals's estimated revenue per employee is $321,600
- Salix Pharmaceuticals's total funding is $750M.
Employee Data
- Salix Pharmaceuticals has 862 Employees.
- Salix Pharmaceuticals grew their employee count by 14% last year.
Salix Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CFO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Sales- GI and Primary Care Divisions | Reveal Email/Phone |
4 | Director, Medical Affairs, Pain & Neurology Team Lead | Reveal Email/Phone |
5 | Director Digital Strategy | Reveal Email/Phone |
6 | Director, Commercial Learning & Development | Reveal Email/Phone |
7 | Senior Director Marketing | Reveal Email/Phone |
8 | Associate Director Medical Affairs | Reveal Email/Phone |
9 | Director, Commercial Analytics | Reveal Email/Phone |
10 | Executive Director Marketing, US Brand Lead | Reveal Email/Phone |
Salix Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Salix Pharmaceuticals?
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases. We offer effective solutions and strive to be the first to discover what patients need next. We gain a deeper understanding of the GI conditions our products treat by connecting with the patients who use them and the healthcare professionals (HCPs) who prescribe them. Our therapeutic areas of expertise include management of conditions such as hepatic encephalopathy, irritable bowel syndrome with diarrhea, opioid-induced constipation, and ulcerative colitis. We employ dedicated and innovated team members who are driven to solve problems. We improve upon existing treatments, uncover new breakthroughs, and deliver comprehensive practice support to help HCPs provide best-in-class care. The landscape of healthcare will continue to change and new patients will continue to present with new needs. That's why there is no finish line for our innovation and no limits to our potential.
keywords:Biotechnology,Healthcare,Pharmaceuticals$750M
Total Funding
862
Number of Employees
$277.2M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Salix Pharmaceuticals News
Allergan, Inc.; Galderma and Salix Pharmaceuticals etc. The report provides a good overview of the key macroeconomic factors that have a...
... Scope And Forecast | Leading Players Salix Pharmaceuticals, ... Impax Laboratories, LLC, Teva Pharmaceutical Industries Ltd.
BRIDGEWATER, N.J., April 7, 2022 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies...
BRIDGEWATER, N.J., June 15, 2021 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced today that data featuring TRULANCE® (plecanatide) will be share ...
Salix Pharmaceuticals Sponsored Report, Patient Perspectives: Living with IBS in a Pandemic Insights May Help Health Care Providers Have Productive Conversations with Their Patients About IBS Symptoms LAVAL, Quebec, April 15, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ...
Salix Pharmaceuticals Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2002-03-12 | $49.8M | Public Offering | Article | |
2003-11-11 | $30.6M | Private Placement | Article | |
2008-08-25 | $60.0M | Undisclosed | Article | |
2012-03-19 | $690.0M | Undisclosed | Article | |
2014-01-13 | $0.8M | Undisclosed | Article |